Case report and literature review: efficacy of afatinib in a rare EGFR p.G719A/p.H773L compound-mutant NSCLC with over 54 months of progression-free survival

Compound EGFR mutations involving an exon 18 sensitizing variant and an exon 20 non-insertion point mutations pose a therapeutic dilemma: the former predicts TKI sensitivity, while the latter is frequently annotated as potentially resistant based solely on genomic location, given the absence of direct functional evidence. Here we describe a 66-year-old female never-smoker with advanced lung adenocarcinoma harboring an EGFR p.G719A (exon 18) and p.H773L (exon 20) compound mutation. Despite the unfavorable annotation of H773L, the patient was treated with first-line afatinib 40 mg daily (with subsequent dose reduction to 30 mg for toxicity management). Disease control was maintained through sequential adjustments, including consolidative radiotherapy for oligoprogression after a brief afatinib treatment interruption. Remarkably, the patient achieved a progression-free survival exceeding 54 months. This duration exceeds the typical 13–15 months median PFS reported for pure G719X mutations and represents an exceptional outcome for this specific genotype. These data provide the first clinical evidence that the G719A/H773L compound mutation retains high sensitivity to afatinib, challenging the assumption that all exon 20 non-insertion variants confer TKI resistance. Lacking definitive functional data, our findings support prioritizing the established sensitivity of the dominant driver mutation over theoretical concerns about coexisting variants. This approach offers practical guidance for managing ultra-rare EGFR genotypes.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.3389/fphar.2026.1952109
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case report and literature review: efficacy of afatinib in a rare EGFR p.G719A/p.H773L compound-mutant NSCLC with over 54 months of progression-free survival

Xin Xun, Bin Su, Yunfei Ye, Ziran Gao et al.
1 links
Frontiers in Pharmacology
Lung Cancer Treatments and Mutations
article

Case report and literature review: efficacy of afatinib in a rare EGFR p.G719A/p.H773L compound-mutant NSCLC with over 54 months of progression-free survival

Xin Xun, Bin Su, Yunfei Ye, Ziran Gao, Meijin Huang, Xunzhi Zhu, Qingxia Yang, Jun Zhu, Hong Chen, Yi Li
article en

Abstract

Compound EGFR mutations involving an exon 18 sensitizing variant and an exon 20 non-insertion point mutations pose a therapeutic dilemma: the former predicts TKI sensitivity, while the latter is frequently annotated as potentially resistant based solely on genomic location, given the absence of direct functional evidence. Here we describe a 66-year-old female never-smoker with advanced lung adenocarcinoma harboring an EGFR p.G719A (exon 18) and p.H773L (exon 20) compound mutation. Despite the unfavorable annotation of H773L, the patient was treated with first-line afatinib 40 mg daily (with subsequent dose reduction to 30 mg for toxicity management). Disease control was maintained through sequential adjustments, including consolidative radiotherapy for oligoprogression after a brief afatinib treatment interruption. Remarkably, the patient achieved a progression-free survival exceeding 54 months. This duration exceeds the typical 13–15 months median PFS reported for pure G719X mutations and represents an exceptional outcome for this specific genotype. These data provide the first clinical evidence that the G719A/H773L compound mutation retains high sensitivity to afatinib, challenging the assumption that all exon 20 non-insertion variants confer TKI resistance. Lacking definitive functional data, our findings support prioritizing the established sensitivity of the dominant driver mutation over theoretical concerns about coexisting variants. This approach offers practical guidance for managing ultra-rare EGFR genotypes.

Frontiers in PharmacologyVol. 17
Chinese People's Liberation Army (CN)
Yunnan Provincial Science and Technology Department
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon